Tag: FDA guidance

Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials

Posted on digi By digi

Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials How to Secure FDA Orphan Drug Designation in Rare Disease Clinical Trials Understanding the FDA Orphan Drug Designation The Orphan Drug Designation (ODD) program, administered by the U.S. Food and Drug Administration (FDA), was established under the Orphan Drug Act of 1983 to…

Read More “Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials” »

Rare and Orphan Disease Trials, Regulatory Frameworks

Data Monitoring Committees in Small Population Studies: Roles and Challenges

Posted on digi By digi

Data Monitoring Committees in Small Population Studies: Roles and Challenges Overseeing Rare Disease Trials: The Role of Data Monitoring Committees in Small Populations Why Data Monitoring Committees Are Crucial in Rare Disease Research Data Monitoring Committees (DMCs), also known as Data and Safety Monitoring Boards (DSMBs), are independent groups tasked with safeguarding patient safety and…

Read More “Data Monitoring Committees in Small Population Studies: Roles and Challenges” »

Operational Challenges, Rare and Orphan Disease Trials

FDA Expectations for Natural History Evidence in Rare Disease Trials

Posted on digi By digi

FDA Expectations for Natural History Evidence in Rare Disease Trials Meeting FDA Expectations for Natural History Data in Rare Disease Development Introduction: The Regulatory Role of Natural History in Rare Diseases Natural history studies have become a regulatory cornerstone in the development of therapies for rare diseases. The U.S. Food and Drug Administration (FDA) recognizes…

Read More “FDA Expectations for Natural History Evidence in Rare Disease Trials” »

Natural History Studies, Rare and Orphan Disease Trials

Long-Term Efficacy Data in Rare Disease Gene Therapy Programs

Posted on digi By digi

Long-Term Efficacy Data in Rare Disease Gene Therapy Programs Assessing Long-Term Efficacy in Gene Therapy for Rare Diseases Introduction: Why Long-Term Data Matters in Gene Therapy Gene therapy has emerged as a transformative treatment for rare diseases, offering the possibility of one-time interventions that deliver lasting clinical benefit. However, regulators, clinicians, and patients alike require…

Read More “Long-Term Efficacy Data in Rare Disease Gene Therapy Programs” »

Case Studies & Breakthroughs, Rare and Orphan Disease Trials